The Saudi Heart Association announced on Saturday that it has signed a memorandum of understanding with AstraZeneca, aimed at cooperating in the field of cardiovascular health and contributing to turning scientific knowledge and innovation into tangible progress in clinical practice and patient care in Saudi Arabia.
Background to the Memorandum
The memorandum comes as cardiovascular disease represents a major public health challenge in Saudi Arabia, and as its prevention and management require integrated efforts among health institutions, medical associations and the pharmaceutical industry, helping to link scientific evidence to everyday clinical practice, and to ensure early detection of patients and their access to appropriate care.
Areas of Cooperation
The initial areas of cooperation include supporting the generation of scientific evidence through studies and health research in the field of heart disease, and strengthening scientific exchange through scientific conferences and forums and building the capacities of healthcare practitioners in cardiology specialties, along with developing care for patients with high blood pressure by helping to improve cardiac care policies, their quality, efficiency and pathways in Saudi Arabia.
This cooperation reflects AstraZeneca's commitment to supporting Saudi Arabia's health transformation journey in line with the targets of Vision 2030, going beyond the provision of innovative medicines to contributing to the development of the healthcare delivery system.
Statements from Both Sides
Dr. Walid Al-Habib, President of the Saudi Heart Association, affirmed that improving heart disease treatment outcomes in Saudi Arabia requires coordinated and ambitious work at the level of the health system, explaining that cooperation with AstraZeneca strengthens the Association's ability to generate scientific evidence, empower healthcare personnel, and raise cardiac care standards, enabling more patients to enjoy longer and healthier lives.
He described the signing of the memorandum as the beginning of a long-term cooperation path between the two sides, which contributes to improving heart health among members of society across Saudi Arabia.
For his part, Hatem Wardani, President of AstraZeneca in Saudi Arabia, explained that about 6.1 million adults in Saudi Arabia have high blood pressure, and that blood pressure remains uncontrolled in about 4.7 million of them, according to the World Health Organization's 2025 report, stressing that addressing this challenge requires more than medication and calls for a partnership based on science and a shared vision.
He expressed his welcome of the cooperation with the Saudi Heart Association, pointing to its commitment to turning this cooperation into practical steps that translate scientific knowledge and innovation into a tangible positive impact on patients' lives, in support of the targets of Vision 2030.
Source: Arriyadiyah newspaper

Comments (0)